相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice
Yueming Chen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review
Zheng Li et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis
Zheng Li et al.
PHARMACOLOGICAL RESEARCH (2020)
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents
Zheng Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold
Zheng Li et al.
BIOORGANIC CHEMISTRY (2019)
Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges
Zheng Li et al.
MEDICINAL RESEARCH REVIEWS (2018)
Complex Pharmacology of Free Fatty Acid Receptors
Graeme Milligan et al.
CHEMICAL REVIEWS (2017)
Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
Zheng Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
Zheng Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development
Zheng Li et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875
Ankita Srivastava et al.
NATURE (2014)
Optimization of GPR40 Agonists for Type 2 Diabetes
Jiwen (Jim) Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
Venkategowda Sunil et al.
BMC PHARMACOLOGY & TOXICOLOGY (2014)
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
Yingcai Wang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
AMG 837: A potent, orally bioavailable GPR40 agonist
Jonathan B. Houze et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist
Sean P. Brown et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists
Shinobu Sasaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist
Nobuyuki Negoro et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Fatty acid receptors as new therapeutic targets for diabetes
Geetha Vani Rayasam et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Sulfonylurea induced beta-cell apoptosis in cultured human islets
K Maedler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
分享论文
